Urotensin II enhances transforming growth factor‑β1 expression and secretion in the kidney during aristolochic acid nephropathy

Chen,Suxian; Wang,Yadi; Wan,Yizeng

doi:10.3892/mmr.2017.7424

Urotensin II enhances transforming growth factor‑β1 expression and secretion in the kidney during aristolochic acid nephropathy

Authors:
- Suxian Chen
- Yadi Wang
- Yizeng Wan
View Affiliations

Affiliations: Department of Pathology, The Third Hospital Affiliated to The Liaoning Medical University, Jinzhou, Liaoning 121001, P.R. China, Department of Oncology, The Third Hospital Affiliated to The Liaoning Medical University, Jinzhou, Liaoning 121001, P.R. China
Published online on: September 5, 2017 https://doi.org/10.3892/mmr.2017.7424
Pages: 6904-6909

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aristolochic acid is a component of many types of Chinese medicine, which are commonly used to treat almost all human diseases. However, aristolochic acid may cause nephropathy. Urotensin II (UII) and transforming growth factor (TGF)‑β1 are important signaling factors, which are expressed at elevated levels during the development of nephropathy. However, the association between UII and TGF‑β1 expression remains unclear. In the current study, the regulatory association between UII and TGF‑β1 expression was investigated using a rat aristolochic acid nephropathy model and the NRK‑52E cell line. The expression levels of UII and TGF‑β1 were identified to be constantly increased in the rat aristolochic acid nephropathy model, even 10 days after administration of Aristolochiae manshuriensis decoction was terminated. Notably, increases in the TGF‑β1 expression levels occurred later than those of UII. Furthermore, UII enhanced TGF‑β1 expression in, and secretion from, NRK‑52E cells. These data indicate that UII and TGF‑β1 are important in the development of aristolochic acid nephropathy, and UII enhances TGF‑β1 expression levels and secretion during aristolochic acid nephropathy. However, the underlying mechanisms for the precise roles of UII and TGF‑β1 as well as the method by which UII regulates the expression TGF‑β1 in aristolochic acid nephropathy remain to be elucidated in future studies.

View Figures

View References

1	Jong TT, Lee MR, Hsiao SS, Hsai JL, Wu TS, Chiang ST and Cai SQ: Analysis of aristolochic acid in nine sources of Xixin, a traditional Chinese medicine, by liquid chromatography/atmospheric pressure chemical ionization/tandem mass spectrometry. J Pharm Biomed Anal. 33:831–837. 2003. View Article : Google Scholar : PubMed/NCBI
2	Wang HT, Wang YM, Liang YP, Liu YJ and Peng W: Wenyang Huoxue Recipe up-regulates the expression of angiopoietin-1 mRNA in rats with chronic aristolochic acid nephropathy. Zhong Xi Yi Jie He Xue Bao. 6:508–511. 2008.(In Chinese). View Article : Google Scholar : PubMed/NCBI
3	Grollman AP: Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease. Environ Mol Mutagen. 54:1–7. 2013. View Article : Google Scholar : PubMed/NCBI
4	Nortier JL, Schmeiser HH, Martinez MC Muniz, Arlt VM, Vervaet C, Garbar CH, Daelemans P and Vanherweghem JL: Invasive urothelial carcinoma after exposure to Chinese herbal medicine containing aristolochic acid may occur without severe renal failure. Nephrol Dial Transplant. 18:426–428. 2003. View Article : Google Scholar : PubMed/NCBI
5	Vanherweghem JL, Depierreux M, Tielemans C, Abramdwicz D, Dratwa M, Jadoul M, Richard C, Vandervelde D, Verbeelen D, Vanhaelen-Fastre R, et al: Rapidly progressive interstitial renal fibrosis in young women: Association with slimming regimen including Chinese herds. Lancet. 341:387–391. 1993. View Article : Google Scholar : PubMed/NCBI
6	Vaudry H, Leprince J, Chatenet D, Fournier A, Lambert DG, Le Mével JC, Ohlstein EH, Schwertani A, Tostivint H and Vaudry D: International union of basic and clinical pharmacology. XCII. Urotensin II, urotensin II-related peptide, and their receptor: From structure to function. Pharmacol Rev. 67:214–258. 2015. View Article : Google Scholar : PubMed/NCBI
7	Egginger JG, Camus A and Calas A: Urotensin-II expression in the mouse spinal cord. J Chem Neuroanat. 31:146–154. 2006. View Article : Google Scholar : PubMed/NCBI
8	Jegou S, Cartier D, Dubessy C, Gonzalez BJ, Chatenet D, Tostivint H, Scalbert E, LePrince J, Vaudry H and Lihrmann I: Localization of the urotensin II receptor in the rat central nervous system. J Comp Neurol. 495:21–36. 2006. View Article : Google Scholar : PubMed/NCBI
9	Diebold I, Petry A, Burger M, Hess J and Görlach A: NOX4 mediates activation of FoxO3a and matrix metalloproteinase-2 expression by urotensin-II. Mol Biol Cell. 22:4424–4434. 2011. View Article : Google Scholar : PubMed/NCBI
10	Lu W, Abdel-Razik AE, Ashton N and Balment RJ: Urotensin II: Lessons from comparative studies for general endocrinology. Gen Comp Endocrinol. 157:14–20. 2008. View Article : Google Scholar : PubMed/NCBI
11	Richards AM and Charles C: Urotensin II in the cardiovascular system. Peptides. 25:1795–1802. 2004. View Article : Google Scholar : PubMed/NCBI
12	Chen SX, Li C, Miao CS, Zhang XY and Fan Z: Mitogenic effect of urotensin II on the renal tubular epithelial cells in rats. J Jilin Univ (Med Ed). 33:204–206. 2007.(In Chinese).
13	Sue YM, Chen CH, Hsu YH, Hou CC, Cheng CY, Chen YC, Lin SL, Chen TW and Chen TH: Urotensin II induces transactivation of the epidermal growth factor receptor via transient oxidation of SHP-2 in the rat renal tubular cell line NRK-52E. Growth Factors. 27:155–162. 2009. View Article : Google Scholar : PubMed/NCBI
14	Abdel-Razik AE, Forty EJ, Balment RJ and Ashton N: Renal haemodynamic and tubular actions of urotensin II in the rat. J Endocrinol. 198:617–624. 2008. View Article : Google Scholar : PubMed/NCBI
15	Adebiyi A: RGS2 regulates urotensin II-induced intracellular Ca2+ elevation and contraction in glomerular mesangial cells. J Cell Physiol. 229:502–511. 2014. View Article : Google Scholar : PubMed/NCBI
16	Hsu YH, Chen TH, Chen YC, Cheng CY, Sue YM, Chen JR and Chen CH: Urotensin II exerts antiapoptotic effect on NRK-52E cells through prostacyclin-mediated peroxisome proliferator-activated receptor alpha and Akt activation. Mol Cell Endocrinol. 381:168–174. 2013. View Article : Google Scholar : PubMed/NCBI
17	Yilmaz B, Yilmaz A, Sari F, Sarikaya AM, Ellidag HY, Kucukseymen S and Ozpelit E: Decrease of Urotensin II activity can impact on the volume status in predialysis chronic kidney disease. Ren Fail. 37:476–481. 2015. View Article : Google Scholar : PubMed/NCBI
18	Tian L, Li C, Qi J, Fu P, Yu X, Li X and Cai L: Diabetes-induced upregulation of urotensin II and its receptor plays an important role in TGF-beta1-mediated renal fibrosis and dysfunction. Am J Physiol Endocrinol Metab. 295:E1234–E1242. 2008. View Article : Google Scholar : PubMed/NCBI
19	Chen S and Wan Y: The effect of Aristolochic acid on UII and GPR14 mRNA levels in the renal tubular epithelial cells. Shandong Pharm. 52:36–38. 2012.(In Chinese).
20	Ruiz-Torres MP, Bosch RJ, O'Valle F, Del Moral RG, Ramírez C, Masseroli M, Pérez-Caballero C, Iglesias MC, Rodríguez-Puyol M and Rodríguez-Puyol D: Age-related increase in expression of TGF-beta1 in the rat kidney: Relationship to morphologic changes. J Am Soc Nephrol. 9:782–791. 1998.PubMed/NCBI
21	Lúdvíksson BR, Seegers D, Resnick AS and Strober W: The effect of TGF-beta1 on immune responses of naive versus memory CD4+ Th1/Th2 T cells. Eur J Immunol. 30:2101–2111. 2000. View Article : Google Scholar : PubMed/NCBI
22	Zeng H, Zhou Y and Yao GY: Transforming growth factor beta 1 induces the transdifferentiation of human renal tubular epithelial cells: the influence of Notch1 receptor specific inhibitor. Chin J Clin Rehabilitative Tissue Engineering Res. 18:8261–8268. 2014.(In Chinese).
23	Docherty NG, Pérez-Barriocanal F, Balboa NE and López-Novoa JM: Transforming growth factor-beta1 (TGF-beta1): A potential recovery signal in the post-ischemic kidney. Ren Fail. 24:391–406. 2002. View Article : Google Scholar : PubMed/NCBI
24	Hwang M, Kim HJ, Noh HJ, Chang YC, Chae YM, Kim KH, Jeon JP, Lee TS, Oh HK, Lee YS and Park KK: TGF-beta1 siRNA suppresses the tubulointerstitial fibrosis in the kidney of ureteral obstruction. Exp Mol Pathol. 81:48–54. 2006. View Article : Google Scholar : PubMed/NCBI
25	Huang XR, Chung AC, Wang XJ, Lai KN and Lan HY: Mice overexpressing latent TGF-beta1 are protected against renal fibrosis in obstructive kidney disease. Am J Physiol Renal Physiol. 295:F118–F127. 2008. View Article : Google Scholar : PubMed/NCBI
26	Basile DP, Martin DR and Hammerman MR: Extracellular matrix-related genes in kidney after ischemic injury: Potential role for TGF-beta in repair. Am J Physiol. 275:F894–F903. 1998.PubMed/NCBI
27	Spurgeon KR, Donohoe DL and Basile DP: Transforming growth factor-beta in acute renal failure: Receptor expression, effects on proliferation, cellularity, and vascularization after recovery from injury. Am J Physiol Renal Physiol. 288:F568–F577. 2005. View Article : Google Scholar : PubMed/NCBI
28	Gobe G, Zhang XJ, Willgoss DA, Schoch E, Hogg NA and Endre ZH: Relationship between expression of Bcl-2 genes and growth factors in ischemic acute renal failure in the rat. J Am Soc Nephrol. 11:454–467. 2000.PubMed/NCBI
29	Kemp W, Kompa A, Phrommintikul A, Herath C, Zhiyuan J, Angus P, McLean C, Roberts S and Krum H: Urotensin II modulates hepatic fibrosis and portal hemodynamic alterations in rats. Am J Physiol Gastrointest Liver Physiol. 297:G762–G767. 2009. View Article : Google Scholar : PubMed/NCBI
30	Zhang YG, Hu YC, Mao YY, Wei RH, Bao SL, Wu LB and Kuang ZJ: Transforming growth factor-β1 involved in urotensin II-induced phenotypic differentiation of adventitial fibroblasts from rat aorta. Chin Med J (Engl). 123:3634–3639. 2010.PubMed/NCBI
31	Weiskirchen R and Meurer SK: BMP-7 counteracting TGF-beta1 activities in organ fibrosis. Front Biosci (Landmark Ed). 18:1407–1434. 2013. View Article : Google Scholar : PubMed/NCBI
32	Samarakoon R, Overstreet JM, Higgins SP and Higgins PJ: TGF-β1→SMAD/p53/USF2→PAI-1 transcriptional axis in ureteral obstruction-induced renal fibrosis. Cell Tissue Res. 347:117–128. 2012. View Article : Google Scholar : PubMed/NCBI
33	Dai HY, He T, Li XL, Xu WL and Ge ZM: Urotensin-2 promotes collagen synthesis via ERK1/2-dependent and ERK1/2-independent TGF-β1 in neonatal cardiac fibroblasts. Cell Biol Int. 35:93–98. 2011. View Article : Google Scholar : PubMed/NCBI
34	Onat AM, Turkbeyler IH, Pehlivan Y, Demir T, Kaplan DS, Taysi S, Ceribasi AO, Tutar E and Kisacik B: The efficiency of a urotensin II antagonist in an experimental lung fibrosis model. Inflammation. 35:1138–1143. 2012. View Article : Google Scholar : PubMed/NCBI
35	Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, Kelly DJ, Gilbert RE and Krum H: Direct actions of urotensin II on the heart: Implications for cardiac fibrosis and hypertrophy. Circ Res. 93:246–253. 2003. View Article : Google Scholar : PubMed/NCBI
36	Zhang YG, Li YG, Liu BG, Wei RH, Wang DM, Tan XR, Bu DF, Pang YZ and Tang CS: Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol. Acta Pharmacol Sin. 28:36–43. 2007. View Article : Google Scholar : PubMed/NCBI